ANNX - Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting | Benzinga
Protective Effects of ANX007 on Visual Acuity and Vision Related Anatomical Measures in the Central Macula Will be Presented as a Late-Breaking Oral Presentation
Topline Phase 2 ARCHER Trial Results Will be Discussed as an Oral Presentation
BRISBANE, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing novel therapies for neuroinflammatory diseases of the body, brain, and eye, today announced the Company will have two presentations at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting being held July 17-20, 2024 in Stockholm, Sweden.
Details of the presentations are as follows:
Late Breaking Oral Presentation: "Protective Effects of ANX007 on Central Macular Ellipsoid Zone (EZ) and Retinal Pigment Epithelium (RPE) and Association with Visual Acuity in the Phase 2 ARCHER GA Study"
- Session: Imaging Symposium I
- Presenter: Dr. Glenn J. Jaffe, Duke Department of Ophthalmology, North Carolina
- Date/Time: Thursday, July 18, 2024, 8:42 - 8:46 am ET
- Location: Stockholmsmässan Convention Center
Oral Presentation: "Preservation of Vision by ANX007: Clinical Results and Anatomic Changes From the Phase 2 ARCHER Trial"
- Session: Dry AMD Symposium 2
- Presenter: Dr. Joel Pearlman, Retinal Consultants Medical Group
- Date/Time: Thursday, July 18, 2024, 1:36 - 1:40 pm ET
- Location: Stockholmsmässan Convention Center
About ANX007 and Phase 2 ARCHER Trial
ANX007 is an antigen-binding fragment (Fab) antibody designed as a first-in-kind therapeutic to selectively inhibit C1q, the initiating molecule of the classical complement pathway and a key driver of neurodegeneration. In GA, C1q binds to photoreceptor synapses early in the disease process, causing aberrant activation of the classical pathway with synapse loss, inflammation and neuronal damage that results in vision loss. Intravitreal administration of ANX007 fully stops C1q and classical pathway activation. In animal models, the murine analog of ANX007 protects against loss of photoreceptor synapses and cells to preserve function. ANX007 has been granted Fast Track designation from the Food and Drug Administration and is the first therapeutic candidate for the treatment of GA to receive Priority Medicine (PRIME) designation in the EU, which provides early and proactive support to developers of promising medicines that may offer a major therapeutic advantage over existing treatments or benefit to patients without treatment options.
In the randomized, multi-center, double-masked, sham-controlled Phase 2 ARCHER clinical trial, ANX007 demonstrated consistent protection ...